Study to Evaluate the Efficacy and Safety of MEDI9929 (AMG 157) in Adult Subjects With Inadequately Controlled, Severe Asthma
2018年11月5日 更新者：MedImmune LLC
A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI9929 in Adult Subjects With Inadequately Controlled, Severe Asthma
The primary objective of the study is to evaluate the effect of 3 dose levels of MEDI9929 (AMG 157) on asthma exacerbations in adult subjects with inadequately controlled, severe asthma.
研究概览
研究类型
介入性
注册 (实际的)
584
阶段
- 阶段2
联系人和位置
本节提供了进行研究的人员的详细联系信息，以及有关进行该研究的地点的信息。
学习地点
-
-
-
Dnipropetrovsk、乌克兰、49051
- Research Site
-
Ivano-Frankivsk、乌克兰、76012
- Research Site
-
Kyiv、乌克兰、04050
- Research Site
-
Kyiv、乌克兰、02091
- Research Site
-
Kyiv、乌克兰、03680
- Research Site
-
Mykolayiv、乌克兰、54003
- Research Site
-
Odessa、乌克兰、65039
- Research Site
-
Poltava、乌克兰、36038
- Research Site
-
Suprunivka Vil., Poltava Regio、乌克兰、36028
- Research Site
-
Vinnytsia、乌克兰、21029
- Research Site
-
Zaporizhzhya、乌克兰、69600
- Research Site
-
Zaporizhzhya、乌克兰、69035
- Research Site
-
-
-
-
-
Ashkelon、以色列、78278
- Research Site
-
Haifa、以色列、34362
- Research Site
-
Jerusalem、以色列、91120
- Research Site
-
Kfar-Saba、以色列、44281
- Research Site
-
Petach Tikva、以色列
- Research Site
-
Rehovot、以色列、7661041
- Research Site
-
Tel Hashomer、以色列、52621
- Research Site
-
-
-
-
-
Plovdiv、保加利亚、4002
- Research Site
-
Sofia、保加利亚、1431
- Research Site
-
Sofia、保加利亚、1202
- Research Site
-
Sofia、保加利亚、1233
- Research Site
-
Sofia、保加利亚、1750
- Research Site
-
Sofia、保加利亚、1606
- Research Site
-
Velingrad、保加利亚、4600
- Research Site
-
-
-
-
-
Balassagyarmat、匈牙利、2660
- Research Site
-
Budapest、匈牙利、1125
- Research Site
-
Budapest、匈牙利、1529
- Research Site
-
Budapest、匈牙利、1033
- Research Site
-
Csorna、匈牙利、9300
- Research Site
-
Debrecen、匈牙利、4032
- Research Site
-
Farkasgyepü、匈牙利、8582
- Research Site
-
Gödöllő、匈牙利、2100
- Research Site
-
Komarom、匈牙利、2900
- Research Site
-
Mateszalka、匈牙利、4700
- Research Site
-
Nagykanizsa、匈牙利、8800
- Research Site
-
Szeged、匈牙利、H-6722
- Research Site
-
Százhalombatta、匈牙利、2440
- Research Site
-
Torokbalint、匈牙利、2045
- Research Site
-
-
-
-
-
Durban、南非、4068
- Research Site
-
Middelburg、南非、1055
- Research Site
-
Pretoria、南非、0181
- Research Site
-
Pretoria、南非、0183
- Research Site
-
-
-
-
-
Belgrade、塞尔维亚、11000
- Research Site
-
Kragujevac、塞尔维亚、34000
- Research Site
-
Sremska Kamenica、塞尔维亚、21204
- Research Site
-
-
-
-
-
Daugavpils、拉脱维亚、LV-5401
- Research Site
-
Rezekne、拉脱维亚、LV-4600
- Research Site
-
Riga、拉脱维亚、1001
- Research Site
-
Riga、拉脱维亚、LV1002
- Research Site
-
Riga、拉脱维亚、LV-1038
- Research Site
-
Riga、拉脱维亚、LV1010
- Research Site
-
-
-
-
-
Brandys nad Labem、捷克语、250 01
- Research Site
-
Hradec Kralove、捷克语、500 05
- Research Site
-
Mlada Boleslav、捷克语、293 01
- Research Site
-
Praha 4、捷克语、14059
- Research Site
-
Praha 8、捷克语、180 81
- Research Site
-
Praha 8、捷克语、180 00
- Research Site
-
Strakonice、捷克语、38601
- Research Site
-
-
-
-
-
Bardejov、斯洛伐克、085 01
- Research Site
-
Bratislava、斯洛伐克、84108
- Research Site
-
Ilava、斯洛伐克、01901
- Research Site
-
Kosice、斯洛伐克、040 01
- Research Site
-
Levice、斯洛伐克、934 01
- Research Site
-
Nove Zamky、斯洛伐克、940 01
- Research Site
-
Poprad、斯洛伐克、058 01
- Research Site
-
Spisska Nova Ves、斯洛伐克、052 01
- Research Site
-
Sturovo、斯洛伐克、94301
- Research Site
-
Surany、斯洛伐克、94201
- Research Site
-
Topolcany、斯洛伐克、95501
- Research Site
-
Zvolen、斯洛伐克、96001
- Research Site
-
-
-
-
-
Chuo-ku、日本、103-0028
- Research Site
-
Chuo-ku、日本、103-0027
- Research Site
-
Chuo-ku、日本、104-8560
- Research Site
-
Fujisawa-shi、日本、251-8550
- Research Site
-
Kiyose-shi、日本、204-8585
- Research Site
-
Kurume-shi、日本、830-0011
- Research Site
-
Maebashi-shi、日本、371-0054
- Research Site
-
Ora-gun、日本、370-0615
- Research Site
-
Sagamihara-shi、日本、228-0815
- Research Site
-
Saitama-Ken、日本、338-8553
- Research Site
-
Sapporo-shi、日本、060-0033
- Research Site
-
Taito-ku、日本、111-0051
- Research Site
-
Toshima-ku、日本、171-0014
- Research Site
-
Yokkaichi-shi、日本、510-8567
- Research Site
-
-
-
-
-
Kaunas、立陶宛、LT50009
- Research Site
-
Klaipeda、立陶宛、92288
- Research Site
-
Klaipeda、立陶宛、92231
- Research Site
-
-
-
-
California
-
Los Angeles、California、美国、90025
- Research Site
-
Los Angeles、California、美国、90048
- Research Site
-
-
Florida
-
Miami、Florida、美国、33133
- Research Site
-
Oviedo、Florida、美国、32765
- Research Site
-
-
Georgia
-
Savannah、Georgia、美国、31406
- Research Site
-
-
Illinois
-
Peoria、Illinois、美国、61602
- Research Site
-
-
Maryland
-
Baltimore、Maryland、美国、21224
- Research Site
-
-
Minnesota
-
Rochester、Minnesota、美国、55905
- Research Site
-
-
New York
-
New York、New York、美国、10016
- Research Site
-
New York、New York、美国、10029
- Research Site
-
-
North Carolina
-
Charlotte、North Carolina、美国、28277
- Research Site
-
Charlotte、North Carolina、美国、28207
- Research Site
-
-
Ohio
-
Dublin、Ohio、美国、43016
- Research Site
-
-
Oklahoma
-
Oklahoma City、Oklahoma、美国、73120
- Research Site
-
-
South Carolina
-
Rock Hill、South Carolina、美国、29732
- Research Site
-
Spartanburg、South Carolina、美国、29303
- Research Site
-
-
Texas
-
Houston、Texas、美国、77070
- Research Site
-
-
Virginia
-
Richmond、Virginia、美国、23220
- Research Site
-
-
参与标准
研究人员寻找符合特定描述的人，称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
18年 至 75年 (成人、年长者)
接受健康志愿者
不
有资格学习的性别
全部
描述
Inclusion Criteria:
- Age 18 through 75
- Body mass index (BMI) between 18-40 kg/m2 and weight greater than or equal 40 kg
- Documented physician-diagnosed asthma - Subjects must have received a physician-prescribed asthma controller regimen with medium- or high-dose inhaled corticosteroids (ICS) plus long acting β2 agonist (LABA) -If on asthma controller medications in addition to ICS plus LABA, the dose of the other asthma controller medications (leukotriene receptor inhibitors, theophylline, secondary ICS, long-acting anti-muscarinics (LAMA), cromones, or maintenance oral prednisone or equivalent up to a maximum of 10 mg daily or 20 mg every other day for the maintenance treatment of asthma) must be stable. -Subjects must have a documented history of at least 2 asthma exacerbation events OR at least 1 severe asthma exacerbation resulting in hospitalization within the 12 months prior to first study visit.
Exclusion Criteria:
- Diagnosis of vocal cord dysfunction, reactive airways dysfunction syndrome, hyperventilation and panic attacks, or other mimics of asthma.
- Current smokers or subjects with a smoking history of ≥ 10 pack years
- Former smokers with < 10 pack years must have stopped for at least 1 year to be eligible.
- Any concomitant respiratory disease that in the opinion of the investigator and/or medical monitor will interfere with the evaluation of the investigational product or interpretation of subject safety or study results (eg, chronic obstructive pulmonary disease, cystic fibrosis, pulmonary fibrosis, bronchiectasis, allergic bronchopulmonary aspergillosis, Churg-Strauss syndrome).
- Evidence of active liver disease.
- History of Cancer, except for basal cell carcinoma or insitu carcinoma of the cervix treated with apparent success with curative therapy or other malignancies are eligible provided that curative therapy was completed -Known history of active tuberculosis (TB)
- History of anaphylaxis to any biologic therapy
- Positive medical history for hepatitis B or C
- Subject with human immunodeficiency virus (HIV) or subject taking antiretroviral medications, as determined by medical history and/or subject's verbal report.
学习计划
本节提供研究计划的详细信息，包括研究的设计方式和研究的衡量标准。
研究是如何设计的？
设计细节
- 主要用途：治疗
- 分配：随机化
- 介入模型：并行分配
- 屏蔽：双倍的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
安慰剂比较：Placebo
Participants received placebo matched to MEDI9929 subcutaneously once every 2 weeks from Day 1 to Week 50.
|
Participants received placebo matched to MEDI9929 subcutaneously once every 2 weeks from Day 1 to Week 50.
|
|
实验性的：MEDI9929 70 mg
Participants received 70 milligram (mg) of MEDI9929 subcutaneously once every 4 weeks from Day 1 to Week 48 along with subcutaneous placebo once every 4 weeks from Week 2 to Week 50.
|
Participants received 70 milligram (mg) of MEDI9929 subcutaneously once every 4 weeks from Day 1 to Week 48 along with subcutaneous placebo once every 4 weeks from Week 2 to Week 50.
|
|
实验性的：MEDI9929 210 mg
Participants received 210 mg of MEDI9929 subcutaneously once every 4 weeks from Day 1 to Week 48 along with subcutaneous placebo once every 4 weeks from Week 2 to Week 50.
|
Participants received 210 mg of MEDI9929 subcutaneously once every 4 weeks from Day 1 to Week 48 along with subcutaneous placebo once every 4 weeks from Week 2 to Week 50.
|
|
实验性的：MEDI9929 280 mg
Participants received 280 mg of MEDI9929 subcutaneously once every 2 weeks from Day 1 to Week 50.
|
Participants received 280 mg of MEDI9929 subcutaneously once every 2 weeks from Day 1 to Week 50.
|
研究衡量的是什么？
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Annualized Asthma Exacerbation Rate (AER) Through Week 52
大体时间：Week 0 (Day 1) up to Week 52
|
Asthma exacerbation is defined as worsening of asthma that leads to any of the following: use of systemic corticosteroids for at least 3 days, an emergency department visit due to asthma that required systemic corticosteroids, and an inpatient hospitalization due to asthma.
The annual AER was presented as the total number of exacerbations for the treatment group divided by the total duration of person follow-up.
|
Week 0 (Day 1) up to Week 52
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Reduction in AER on Subpopulations at Week 52
大体时间：Week 52
|
Asthma exacerbation is defined as worsening of asthma that leads to any of the following: use of systemic corticosteroids for at least 3 days, an emergency department visit due to asthma that required systemic corticosteroids, and an inpatient hospitalization due to asthma.
Reduction in AER was evaluated in pre-specified subpopulations (blood eosinophil count [eosinophilic and non-eosinophilic], T helper cell 2 [Th2] status [high and low], Fraction of exhaled nitric oxide [FENO] [high and low], serum periostin [high and low], current post bronchodilator forced expiratory volume in 1 second [Post-BD FEV1] reversibility- yes, allergic and non-allergic) of asthma.
The annual AER was presented as the total number of exacerbations for the treatment group divided by the total duration of person follow-up.
Also, the high or low was determined using median value.
|
Week 52
|
|
Change From Baseline in Pre-bronchodilator (Pre-BD) Forced Expiratory Volume in 1 Second (FEV1) and Forced Vital Capacity (FVC) at Week 52
大体时间：Baseline (Week 0 [Day 1]) to Week 52
|
Forced expiratory volume in 1 second and forced vital capacity measures taken before bronchodilator use were reported.
|
Baseline (Week 0 [Day 1]) to Week 52
|
|
Change From Baseline in FEV1 on Subpopulations at Week 52
大体时间：Baseline and up to Week 52
|
Forced expiratory volume in one second (FEV1) was evaluated in pre-specified subpopulations of asthma.
The data presented in the below table for this outcome measure is for pre-bronchodilator FEV1.
|
Baseline and up to Week 52
|
|
Change From Baseline in Post-bronchodilator (Post-BD) FEV1 and FVC at Week 52
大体时间：Baseline (Week 0 [Day 1]) to Week 52
|
Forced expiratory volume in 1 second and forced vital capacity measures taken after bronchodilator use were reported.
|
Baseline (Week 0 [Day 1]) to Week 52
|
|
Change From Baseline in Overall Symptoms Score on Subpopulations at Week 52
大体时间：Baseline and up to Week 52
|
Asthma symptoms during night time and daytime are recorded by the participant in the asthma daily diary.
Overall symptom score is the average of scores of daytime severity, daytime frequency, and nighttime severity symptoms.
The daytime frequency and severity items are scored from 0 to 4, where a higher score indicates greater frequency/severity and nighttime severity item is scored from 0 to 4 , where a higher score indicates greater severity.
Overall symptom score ranges from 0 to 4, where lower score indicates better asthma symptom while, higher score indicates worse asthma symptom.
|
Baseline and up to Week 52
|
|
Change From Baseline in Asthma Symptoms Measured by Asthma Daily Diary at Week 52
大体时间：Baseline (Week 0 [Day 1]) and Week 52
|
Asthma symptoms during night time and daytime are recorded by the participant in the asthma daily diary.
Symptom score values for night time assessment is 0 (no asthma symptom) to 3 (unable to sleep because of asthma) and symptom score values for day time assessment is 0 (no asthma symptom) to 3 (unable to do normal activities due to asthma).
Total asthma symptom score is the sum of the daytime and night time score (0 to 6).
Lower score (0) is indicating better asthma symptom, while higher score (6) is indicating worse asthma symptom.
|
Baseline (Week 0 [Day 1]) and Week 52
|
|
Change From Baseline in Asthma Symptoms Measured by Asthma Control Questionnaire (ACQ-6) Score at Week 52
大体时间：Baseline (Week 0 [Day 1]) and Week 52
|
The ACQ is a patient-reported questionnaire assessing asthma symptoms (ie, night-time waking, symptoms on waking, activity limitation, shortness of breath, wheezing) and daily rescue bronchodilator use and FEV1.
The ACQ-6 is a shortened version of the ACQ that omits the FEV1 measurement from the original ACQ score.
Questions are weighted equally and scored from 0 (totally controlled) to 6 (severely uncontrolled).
|
Baseline (Week 0 [Day 1]) and Week 52
|
|
Rate of Severe Asthma Exacerbation Through Week 52
大体时间：Week 0 (Day 1) up to Week 52
|
A severe asthma exacerbation is defined as an event that resulted in hospitalization.
The severe AER was presented as the total number of exacerbations for the treatment group divided by the total duration of person follow-up.
|
Week 0 (Day 1) up to Week 52
|
|
Time to First Asthma Exacerbation Through Week 52
大体时间：Week 0 (Day 1) through Week 52
|
Asthma exacerbation is defined as worsening of asthma that leads to use of systemic corticosteroids for at least 3 days, an emergency department visit due to asthma that required systemic corticosteroids, and an inpatient hospitalization due to asthma.
Time to first asthma exacerbation was reported.
|
Week 0 (Day 1) through Week 52
|
|
Time to First Severe Asthma Exacerbation Through Week 52
大体时间：Week 0 (Day 1) through Week 52
|
Asthma exacerbation is defined as worsening of asthma that leads to use of systemic corticosteroids for at least 3 days, an emergency department visit due to asthma that required systemic corticosteroids, and an inpatient hospitalization due to asthma.
Time to first severe asthma exacerbations (hospitalization) were reported.
|
Week 0 (Day 1) through Week 52
|
|
Number of Participants With at Least One Asthma Exacerbations Through Week 52
大体时间：Week 0 (Day 1) through Week 52
|
Asthma exacerbation is defined as worsening of asthma that leads to use of systemic corticosteroids for at least 3 days, an emergency department visit due to asthma that required systemic corticosteroids, and an inpatient hospitalization due to asthma.
|
Week 0 (Day 1) through Week 52
|
|
Number of Participants With at Least One Severe Asthma Exacerbations Through Week 52
大体时间：Week 0 (Day 1) through Week 52
|
Asthma exacerbation is defined as worsening of asthma that leads to use of systemic corticosteroids for at least 3 days, an emergency department visit due to asthma that required systemic corticosteroids, and an inpatient hospitalization due to asthma.
Participants with severe asthma exacerbations (hospitalization) were reported.
|
Week 0 (Day 1) through Week 52
|
|
Change From Baseline in Asthma Quality of Life Questionnaire (Standardized Version) (AQLQ [S]) Overall Score at Week 52
大体时间：Baseline (Week 0 [Day 1]) and Week 52
|
The AQLQ(S) +12 is a 32-item questionnaire that measures the health-related quality of life experienced by asthma participants.
The questionnaire comprises 4 separate domains (symptoms, activity limitations, emotional function, and environmental stimuli) scaled on a 7-point scale ranging from 7 (no impairment) to 1 (severe impairment).
|
Baseline (Week 0 [Day 1]) and Week 52
|
|
Change From Baseline in European Quality of Life-5 Dimensions 5 Level Version (EQ-5D-5L) Health State Evaluation at Week 52
大体时间：Baseline (Week 0 [Day 1]) and Week 52
|
European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) is a standardized measure of health status of the participant.
The first component is a descriptive system of the respondent's health comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.
Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems.
The responses are used to derive the health state index scores using the United Kingdom (UK) algorithm, with scores ranging from -0.594 to 1.
A higher score indicates better health state.
The second component is a self-perceived health score which is assessed using a visual analogue scale (VAS) that ranged from 0 to 100, where 0 indicated the worst health you can imagine and 100 indicated the best health you can imagine.
|
Baseline (Week 0 [Day 1]) and Week 52
|
|
Total Amount of Study Drug Exposure
大体时间：Week 0 (Day 1) through Week 52
|
The total amount of study drug exposure (in milligram) for the entire study period was summarized.
|
Week 0 (Day 1) through Week 52
|
|
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)
大体时间：Day 1 upto Week 64
|
An adverse event is any unfavourable and unintended signs (including abnormal laboratory findings), symptoms, or diseases temporally associated with use of medicinal product, whether or not considered related to medicinal product.
Serious adverse event is any adverse event that resulted in death, life-threatening, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, is a congenital anomaly/birth defect in offspring of a study participant, is an important medical event that may jeopardize the participant or may require medical intervention.
TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug, for the period until and including the follow-up period (Week 64).
|
Day 1 upto Week 64
|
|
Number of Participants With TEAEs Related to Vital Sign Parameters
大体时间：Day 1 upto Week 64
|
Adverse events observed in participants with clinically significant vital signs abnormalities were assessed.
|
Day 1 upto Week 64
|
|
Number of Participants With TEAEs Related to Clinical Laboratory Evaluation
大体时间：Day 1 upto Week 64
|
An abnormal laboratory finding which required an action or intervention by the investigator, or a finding judged by the investigator to represent a change beyond the range of normal physiologic fluctuation were reported as an adverse event.
Laboratory evaluations of blood and urine samples were performed.
|
Day 1 upto Week 64
|
|
Number of Participants With TEAEs Related to Electrocardiogram Evaluations
大体时间：From the start of study drug administration upto Week 64
|
Adverse events observed in participants with clinically significant electrocardiogram abnormalities were assessed.
|
From the start of study drug administration upto Week 64
|
|
Mean Serum Concentrations of MEDI9929
大体时间：Week 0 (Day 1) to Week 64
|
The mean serum concentrations of MEDI9929 was observed at specified timepoints.
|
Week 0 (Day 1) to Week 64
|
|
Number of Participants With Positive Antibodies to MEDI9929
大体时间：Week 0 (Day 1) to Week 64
|
Blood samples for immunogenicity assessment included the determination of anti-drug antibodies (ADA) for MEDI9929.
The number of participants with positive serum antibodies to MEDI9929 were presented.
|
Week 0 (Day 1) to Week 64
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
合作者
出版物和有用的链接
负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。
一般刊物
- Corren J, Parnes JR, Wang L, Mo M, Roseti SL, Griffiths JM, van der Merwe R. Tezepelumab in Adults with Uncontrolled Asthma. N Engl J Med. 2017 Sep 7;377(10):936-946. doi: 10.1056/NEJMoa1704064. Erratum In: N Engl J Med. 2019 May 23;380(21):2082.
- Corren J, Pham TH, Garcia Gil E, Salapa K, Ren P, Parnes JR, Colice G, Griffiths JM. Baseline type 2 biomarker levels and response to tezepelumab in severe asthma. Allergy. 2022 Jun;77(6):1786-1796. doi: 10.1111/all.15197. Epub 2022 Feb 9.
- Corren J, Ambrose CS, Salapa K, Roseti SL, Griffiths JM, Parnes JR, Colice G. Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma and Perennial Allergy. J Allergy Clin Immunol Pract. 2021 Dec;9(12):4334-4342.e6. doi: 10.1016/j.jaip.2021.07.045. Epub 2021 Aug 3.
- Ly N, Zheng Y, Griffiths JM, van der Merwe R, Agoram B, Parnes JR, Roskos L. Pharmacokinetic and Pharmacodynamic Modeling of Tezepelumab to Guide Phase 3 Dose Selection for Patients With Severe Asthma. J Clin Pharmacol. 2021 Jul;61(7):901-912. doi: 10.1002/jcph.1803. Epub 2021 Jan 16.
- Corren J, Garcia Gil E, Griffiths JM, Parnes JR, van der Merwe R, Salapa K, O'Quinn S. Tezepelumab improves patient-reported outcomes in patients with severe, uncontrolled asthma in PATHWAY. Ann Allergy Asthma Immunol. 2021 Feb;126(2):187-193. doi: 10.1016/j.anai.2020.10.008. Epub 2020 Oct 23.
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查，以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (实际的)
2013年12月13日
初级完成 (实际的)
2016年12月12日
研究完成 (实际的)
2017年3月1日
研究注册日期
首次提交
2013年12月4日
首先提交符合 QC 标准的
2014年2月3日
首次发布 (估计)
2014年2月4日
研究记录更新
最后更新发布 (实际的)
2018年12月4日
上次提交的符合 QC 标准的更新
2018年11月5日
最后验证
2018年11月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.
Placebo的临床试验
-
City of Hope Medical CenterNational Cancer Institute (NCI)主动，不招人造血和淋巴细胞肿瘤 | 骨髓纤维化 | 慢性淋巴细胞白血病 | 缓解期成人急性髓性白血病 | 骨髓增生异常综合症 | 缓解期成人急性淋巴细胞白血病 | 骨髓增殖性肿瘤 | 慢性期慢性粒细胞白血病，BCR-ABL1 阳性 | 成人淋巴母细胞淋巴瘤 | 加速期慢性粒细胞白血病，BCR-ABL1 阳性 | HLA-A*0201 阳性细胞存在 | 巨细胞病毒感染 | 成人霍奇金淋巴瘤 | 成人非霍奇金淋巴瘤美国
-
Mila (bMotion Technologies)完全的
-
Universidad Autonoma de MadridCentro Universitario La Salle完全的